There is no single best medication for colitis because the right treatment depends on the type of colitis you have and how severe it is. Ulcerative colitis, the most common form requiring long-term medication, follows a step-up approach: mild disease starts with anti-inflammatory pills or suppositories, while moderate-to-severe disease may need biologic drugs or immune-targeting pills. Microscopic colitis and infection-related colitis each have their own first-line treatments entirely.
Why the Type of Colitis Matters
“Colitis” simply means inflammation of the colon, but the cause of that inflammation determines which medication works. Ulcerative colitis is a chronic autoimmune condition where the immune system attacks the colon lining. Microscopic colitis causes chronic watery diarrhea but looks normal on a colonoscopy, only showing up under a microscope. Infectious colitis, most commonly caused by C. difficile bacteria, requires antibiotics rather than immune-suppressing drugs. If you don’t yet know which type you have, that’s the first question to answer with your doctor, because the treatments below are organized by diagnosis.
Mild to Moderate Ulcerative Colitis
For most people newly diagnosed with mild to moderate ulcerative colitis, the first medication is a class called 5-ASAs (the most common being mesalamine). These drugs work by reducing inflammation directly in the colon lining. They come in oral tablets, rectal suppositories, and enemas, and the form you use depends on where your inflammation is. If the disease is limited to the rectum, a suppository alone may be enough. If it extends further, oral tablets are added or used on their own.
The standard effective dose for oral mesalamine is 2 to 3 grams per day. A meta-analysis of four trials with nearly 1,800 patients found that standard-dose mesalamine was clearly better than lower doses for keeping people in remission. Higher doses of 4.8 grams per day didn’t show a significant benefit overall, but did make a meaningful difference in two groups: patients under 40, where 90.5% stayed in remission on the high dose compared to 50% on the standard dose, and patients with extensive disease, where remission rates were 90.9% versus 46.7%.
If mesalamine doesn’t work well enough or you can’t tolerate it, the next step is usually budesonide MMX, a steroid designed to release mostly in the colon with fewer body-wide side effects. Beyond that, conventional steroids like prednisone come into play for flares. The typical flare regimen starts at 40 mg daily for one week, then tapers down by 5 mg each week over about eight weeks total. Steroids are effective for getting symptoms under control quickly, but they’re not meant for long-term use because of side effects like bone thinning, weight gain, and mood changes.
Moderate to Severe Ulcerative Colitis
When the disease is more aggressive, anti-inflammatory pills aren’t enough and doctors move to what are called advanced therapies. These are drugs that target specific parts of the immune system driving the inflammation. The 2025 American College of Gastroenterology guidelines list several classes of advanced therapies, and the choice between them involves weighing how quickly you need relief, your other health conditions, and how you feel about the form of treatment (infusion, injection, or pill).
Biologic Drugs
Biologics are proteins given by infusion or injection that block specific immune signals. The oldest and most widely studied are TNF-alpha blockers like infliximab, which is given as an IV infusion every several weeks. These have decades of real-world data behind them and remain a common first choice for moderate-to-severe disease. Adalimumab, another TNF blocker, is a self-injection you can do at home, which some people prefer.
Newer biologics target different pathways. Vedolizumab works specifically on the gut’s immune system rather than suppressing immunity body-wide, which can mean fewer infections. IL-23 inhibitors, including guselkumab, mirikizumab, and risankizumab, are among the newest options and target a signaling protein involved in driving colon inflammation. Ustekinumab blocks a related but broader target. These newer biologics are increasingly favored for their favorable safety profiles, though long-term data is still accumulating compared to TNF blockers.
Small Molecule Pills
JAK inhibitors (tofacitinib and upadacitinib) are oral pills, which is a significant practical advantage over infusions or injections. In a large network meta-analysis published in The Lancet Gastroenterology & Hepatology, upadacitinib ranked highest among all therapies for inducing clinical remission, outperforming infliximab, adalimumab, vedolizumab, and every other compared drug. That raw efficacy makes it appealing, but it comes with important safety trade-offs.
The FDA requires a boxed warning on JAK inhibitors for increased risks of serious heart events, blood clots, cancer (including lymphoma and lung cancer), and death. These warnings stem from a large safety trial of tofacitinib, and the FDA extended them to upadacitinib because it works through the same mechanism. Because of these risks, JAK inhibitors are currently reserved for people who haven’t responded to or can’t tolerate a TNF blocker. If you’re a current or former smoker, or have a history of heart problems or blood clots, these risks are especially relevant to discuss.
S1P receptor modulators (ozanimod and etrasimod) are another oral option. In the ELEVATE phase 3 trials published in The Lancet, etrasimod achieved clinical remission in 27% of patients at 12 weeks compared to 7% on placebo, and 32% at one year. These remission numbers are more modest than what’s seen with JAK inhibitors, but the safety profile is generally more favorable, making them a reasonable option for people who want an oral medication with a lower risk burden.
Staying in Remission Long-Term
Getting symptoms under control is only half the challenge. Staying there requires maintenance therapy, and which drug you use for maintenance usually depends on what got you into remission. People who respond to mesalamine typically stay on it indefinitely. Those who needed biologics or small molecule drugs generally continue them as well.
Thiopurines (most commonly azathioprine) are older immune-suppressing drugs still used for long-term maintenance, particularly when biologics aren’t needed or accessible. A large UK study of nearly 12,000 patients found that thiopurine monotherapy was effective in 52.7% of ulcerative colitis patients, meaning they didn’t need to escalate to biologics or surgery for the duration of treatment. Among those for whom it worked, the median treatment duration was 17 years. At the one-year mark, 76% of UC patients remained on thiopurines without needing escalation; by three years, 69% were still holding steady. For those who eventually needed something stronger, the median time before escalation was 12 years, which is a meaningful stretch of disease control.
Microscopic Colitis
If you have microscopic colitis (collagenous or lymphocytic), the treatment picture is simpler. Budesonide at 9 mg per day for eight weeks is the standard first-line therapy regardless of subtype, per Cleveland Clinic guidelines. If symptoms resolve after those eight weeks, you can stop. If they return, budesonide is restarted at the lowest effective dose, usually 6 mg per day or less, and continued for six to twelve months. Unlike ulcerative colitis, microscopic colitis doesn’t typically require the heavy-hitting biologics or immunosuppressants, and many people do well on budesonide alone.
Infectious Colitis
C. difficile infection is the most common cause of infectious colitis, particularly after antibiotic use or hospital stays. The CDC recommends treating it with a 10-day course of oral vancomycin or fidaxomicin. This is a fundamentally different situation from autoimmune colitis: the goal is to kill the bacteria causing the problem, not to suppress the immune system. If you’ve been told you have C. diff colitis, immune-suppressing drugs would actually make things worse.
How Doctors Choose Between Options
With so many medications available, the decision often comes down to a few practical factors. Disease severity is the biggest one: mild disease starts with mesalamine, moderate-to-severe disease jumps to advanced therapies. Your age and other health conditions matter too. A 25-year-old with no cardiovascular risk factors has more options, including JAK inhibitors, than a 60-year-old former smoker. How you feel about needles versus pills, infusion center visits versus home treatment, and how quickly you need relief all play a role.
Many gastroenterologists now favor IL-23 inhibitors or vedolizumab as a first advanced therapy because they combine strong efficacy with a reassuring safety profile. JAK inhibitors are often held in reserve for people who’ve failed other options, partly due to FDA restrictions and partly due to the boxed warning. TNF blockers remain a solid workhorse, especially infliximab, which has the longest track record. There’s no universally “best” drug, but there is usually a best fit for your specific situation.